Literature DB >> 7959212

Mesalazine induced interstitial nephritis.

P J Thuluvath1, M Ninkovic, J Calam, M Anderson.   

Abstract

5-Aminosalicylic acid (5-ASA) has structural similarities to both phenacetin and aspirin, which are known to cause 'analgesic nephropathy'. Because of the increasing use of 5-ASA, this paper draws attention to two cases of severe interstitial nephritis resulting from 5-ASA and emphasises the importance of monitoring renal functions of patients with inflammatory bowel diseases who are receiving 5-ASA preparations.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7959212      PMCID： PMC1375033          DOI： 10.1136/gut.35.10.1493

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  29 in total

1.  Acute interstitial nephritis due to 5-aminosalicylic acid.

Authors:  R P Mehta
Journal:  CMAJ       Date:  1990-11-15       Impact factor: 8.262

2.  [Chronic interstitial nephritis after treatment with 5-aminosalicylic acid].

Authors:  H V Henning; J Meinhold; T Eisenhauer; F Scheler; H J Gröne
Journal:  Dtsch Med Wochenschr       Date:  1989-07-07       Impact factor: 0.628

3.  Epidemiologic study of abuse of analgesics containing phenacetin. Renal morbidity and mortality (1968-1979).

Authors:  U C Dubach; B Rosner; E Pfister
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

4.  Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.

Authors:  L Staerk Laursen; M Stokholm; K Bukhave; J Rask-Madsen; K Lauritsen
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

5.  Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells.

Authors:  A Ireland; J D Priddle; D P Jewell
Journal:  Clin Sci (Lond)       Date:  1990-01       Impact factor: 6.124

6.  Nephrotoxic lesions from 5-aminosalicylic Acid.

Authors:  I C Calder; C C Funder; C R Green; K N Ham; J D Tange
Journal:  Br Med J       Date:  1972-01-15

7.  Fenoprofen nephropathy: lipoid nephrosis and interstitial nephritis. A possible T-lymphocyte disorder.

Authors:  A Finkelstein; D S Fraley; I Stachura; H A Feldman; D R Gandy; E Bourke
Journal:  Am J Med       Date:  1982-01       Impact factor: 4.965

8.  Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract.

Authors:  B Myers; D N Evans; J Rhodes; B K Evans; B R Hughes; M G Lee; A Richens; D Richards
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

9.  Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

Authors:  O Haagen Nielsen; S Bondesen
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

10.  Influence of intravenous acetylsalicylic acid and sodium salicylate on human renal function and lithium clearance.

Authors:  I W Reimann; E Golbs; C Fischer; J C Frölich
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953
View more
  17 in total

Review 1.  Ulcerative colitis.

Authors:  S Ghosh; A Shand; A Ferguson
Journal:  BMJ       Date:  2000-04-22

2.  Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.

Authors:  Pedro Magalhães-Costa; Leopoldo Matos; Cristina Chagas
Journal:  BMJ Case Rep       Date:  2015-05-02

3.  Late onset interstitial nephritis associated with mesalazine treatment.

Authors:  J Popoola; A F Muller; L Pollock; P O'Donnell; P Carmichael; P Stevens
Journal:  BMJ       Date:  1998-09-19

Review 4.  Advanced and controlled drug delivery systems in clinical disease management.

Authors:  J R Brouwers
Journal:  Pharm World Sci       Date:  1996-10

Review 5.  Hypersensitivity to 5-ASA suppositories.

Authors:  M L Borum; A Ginsberg
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Systemic levels of free 5-aminosalicylic acid depend on the nature of the 5-aminosalicyclic acid derivative and not on disease activity or extent in patients with inflammatory bowel disease.

Authors:  N Mahmud; D G Weir; D Kelleher
Journal:  Ir J Med Sci       Date:  1999 Oct-Dec       Impact factor: 1.568

7.  Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.

Authors:  N Siddique; C Farmer; A F Muller
Journal:  Frontline Gastroenterol       Date:  2014-06-04

8.  Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.

Authors:  Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

9.  Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.

Authors:  R A J Ransford; M J S Langman
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

10.  Interstitial nephritis from mesalazine: case report and literature review.

Authors:  Lois J Arend; James E Springate
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.